The HDAC7 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of SK-HEP-1 cells in which the gene encoding histone deacetylase 7 (HDAC7) has been disrupted. This polyclonal knockout pool provides a heterogeneous loss-of-function model, enabling researchers to study the collective impact of HDAC7 ablation on cellular processes without selecting a single clonal isolate. As a versatile tool, these cells are suitable for investigating HDAC7-dependent signaling pathways and transcriptional regulation in a human hepatic adenocarcinoma background with endothelial characteristics.
SK-HEP-1 is a human cell line derived from the ascitic fluid of a patient with liver adenocarcinoma. It displays a mixed epithelial and endothelial phenotype, expressing markers such as von Willebrand factor (vWF) and CD34, and is widely employed as a model for hepatocellular carcinoma, angiogenesis, and metastatic progression. The dual nature of SK-HEP-1 cells makes them particularly valuable for dissecting the crosstalk between epithelial and endothelial programs in liver cancer.
HDAC7 is a class IIa histone deacetylase that functions as a transcriptional repressor by deacetylating histones and transcription factors. It is a critical regulator of endothelial cell function, angiogenesis, and immune responses. HDAC7 is activated by stimuli such as VEGF, TNF-??, and TGF-??, and is regulated by phosphorylation-dependent nuclear-cytoplasmic shuttling mediated by kinases like CaMK and AMPK. In the nucleus, HDAC7 interacts with corepressors N-CoR and SMRT and deacetylates transcription factors including MEF2 family members (MEF2A/C/D) and HIF-1??, thereby suppressing pro-angiogenic and EndMT-related genes. Downstream targets include MMP10, PDGF-B, and EndMT-associated transcription factors SNAI1 and TWIST1. Its release from MEF2 upon phosphorylation allows activation of gene programs essential for endothelial cell migration and tube formation.
In the SK-HEP-1 context, which combines hepatic adenocarcinoma and endothelial-like features, HDAC7 knockout offers insights into its dual role in tumor biology and vascular mimicry. Loss of HDAC7 is expected to relieve transcriptional repression on MEF2 and HIF-1?? target genes, potentially enhancing angiogenic factor expression and altering endothelial-to-mesenchymal transition (EndMT). This model is thus instrumental for exploring mechanisms of liver cancer aggressiveness, metastasis, and the interplay between hypoxia signaling and histone modification.
These polyclonal knockout cells are amenable to a range of functional assays, including Western blotting for HDAC7 and downstream targets, RT-qPCR for MEF2-responsive genes, migration and invasion assays, and tube formation assays to assess angiogenic capacity. Additionally, immunofluorescence can monitor HDAC7 subcellular localization, while ChIP-qPCR enables examination of histone acetylation changes at MEF2-regulated promoters. Flow cytometry can evaluate endothelial marker expression, and drug sensitivity assays with HDAC inhibitors can support preclinical therapeutic screening. For inquiries regarding this product, please contact Ascent Research.
